What Is Pancragen?
Pancragen peptide is one of the more specialized compounds currently being explored across pancreatic cell peptide and metabolic regulation research circles within the Khavinson bioregulator family. Composed of the amino acid sequence Lys-Glu-Asp-Trp (KEDW), it is a synthetic tetrapeptide analog derived from a peptide originally isolated from bovine pancreatic cells. Researchers have proposed that Pancragen may penetrate cellular membranes and interact with nuclear components in laboratory models, potentially influencing gene transcription and promoting cell differentiation within the pancreas.
Research suggested that Pancragen may up-regulate critical differentiation factors including Ptf1a, Pdx1, Pax6, Foxa2, Nkx2.2, and Pax4 in laboratory settings, which researchers consider essential for the maturation of pancreatic cells. The peptide also appeared to potentially modulate apoptosis-related proteins by reducing the expression of the proapoptotic protein p53 while increasing the antiapoptotic protein Mcl1 in laboratory models, suggesting an antiapoptotic dimension to this metabolic regulation peptide’s research profile.
Pancragen Peptide and Metabolic Dysregulation Research
One of the most actively studied areas of Pancragen peptide research involves its proposed interactions with glucose homeostasis and carbohydrate metabolism in laboratory models. Research by Korkushko et al. explored Pancragen’s potential role in modulating glucose homeostasis in laboratory settings, with Pancragen exposure associated with a significant reduction in fasting glucose levels during a standard glucose tolerance test in these models. Decreased insulin concentrations and a lower insulin resistance index were also observed, with researchers noting that the glucose-related observations appeared to persist following cessation of exposure in these laboratory settings. Researchers noted that the introduction of tetrapeptides appears to be a promising approach for studying the correction of insulin resistance in laboratory models.
Research by Anisimov and Khavinson further explored Pancragen’s potential interactions with the endocrine function of pancreatic cells and metabolic status in aged laboratory models. A reduced rate of glucose utilization was observed in these models compared to younger counterparts, alongside elevated insulin and C-peptide peaks following glucose introduction. Researchers observed that Pancragen exposure resulted in notable improvements in glucose utilization rates and appeared to normalize the dynamics of plasma insulin and C-peptide responses to glucose in laboratory settings, with some metabolic observations persisting up to three weeks after the trial concluded.
Research by Khavinson et al. in murine models of chronic hyperglycemia further suggested that Pancragen may restore endothelial adhesive properties in laboratory models of metabolic dysregulation, with researchers noting homeostatic and endothelioprotective interactions in these experimental settings.
Pancragen Peptide and Pancreatic Cell Function
Building on its metabolic research profile, Pancragen has also been studied for its potential interactions with pancreatic cellular processes in laboratory models, particularly cell differentiation and the regulation of insulin and glucagon secretion.
Research suggested that Pancragen may penetrate cellular membranes and influence the transcription of genes essential for the differentiation of pancreatic cells in laboratory settings. Experimental data from embryonic cultures of pancreatic acinar cells suggested that Pancragen might support the expression of Ptf1a and Pdx1, proteins considered vital for the maturation of these cells, with these interactions appearing more pronounced in older laboratory cell cultures where a decline in these proteins is typically observed.
Research by Kvetnoi et al. using murine models explored Pancragen’s interactions with the functional morphology of the pancreas in laboratory settings. Following exposure to Pancragen in diabetes-induced laboratory models, researchers observed compensatory changes within pancreatic cells and tissue, including an observable increase in support for insulin production by beta cells and a reduction in glucagon production by alpha cells. The proliferative activity of certain pancreatic cells and their apoptotic rates also appeared to normalize in these laboratory models.
Research by Khavinson et al. further suggested that Pancragen may modulate various cellular markers associated with pancreatic cell vitality in laboratory settings. Pancragen exposure was associated with increased expression of MMP2, MMP9, serotonin, CD79alpha, Mcl1, PCNA, and Ki67, alongside a reduction in the proapoptotic protein p53 in these laboratory models, suggesting Pancragen may activate signaling molecules relevant to maintaining or restoring pancreatic cell function in experimental settings.
Pancragen Peptide and Cellular Aging Research
Pancragen has also been studied for its potential interactions with cellular aging processes in laboratory models across different age groups. Research by Khavinson et al. reported a decrease in specific cellular aging biomarkers including caspase-3 and cathepsin B activities following Pancragen exposure in younger murine models. In mature laboratory models, Pancragen exposure was associated with a significant reduction in TNF-α levels and an increase in IGF-1, both considered important markers in cellular aging and metabolic regulation research contexts.
Research by Ashapkin et al. examined the tissue-specific interactions of Pancragen on gene expression in pancreatic cell cultures, finding that alterations in the methylation patterns of PDX1, PAX6, and NGN3 gene promoter regions may be associated with cellular aging in laboratory models and might contribute to changes in gene expression levels in these settings. These findings suggested that modifications in promoter methylation patterns may drive longer-term changes in gene expression during cellular aging in laboratory models. Researchers noted that while Pancragen may influence certain gene methylation patterns, the relationship between methylation and gene expression appears complex and potentially regulated by additional unidentified mechanisms in these experimental settings.
Pancragen Peptide and Cellular Protection Research
Rounding out this pancreatic cell peptide’s broad laboratory research profile, Pancragen has also been proposed to play a protective role against cellular stress and damage in laboratory models. Researchers have hypothesized that Pancragen may moderate oxidative stress in these settings by scavenging free radicals or by supporting endogenous antioxidant defenses.
Additionally, Pancragen may modulate inflammatory responses in laboratory models by potentially downregulating pro-inflammatory cytokines and promoting the expression of anti-inflammatory mediators. Researchers proposed that these protective mechanisms may contribute to the preservation of cellular integrity under stress conditions in laboratory settings, potentially moderating cellular damage in environments of heightened oxidative or inflammatory stress. These observations have added a cellular protection dimension to this metabolic regulation peptide’s expanding laboratory research profile.
References
- Goncharova ND, et al. Impact of tetrapeptide package on the endocrine function of the pancreas in old monkeys. Adv Gerontol. 2014;27(4):662–7.
- Khavinson VKh, et al. Impacts of Pancragen on the differentiation of pancreatic cells during their aging. Bull Exp Biol Med. 2013;154(4):501–504.
- Korkushko OV, et al. Prospects of using Pancragen for correction of metabolic disorders in elderly people. Bull Exp Biol Med. 2011;151(4):454–456.
- Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139–149.
- Khavinson VKh, et al. Impact of Pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus. Bull Exp Biol Med. 2007;144(4):559–562.
- Kvetnoi IM, et al. Impact of tetrapeptide Pancragen on functional morphology of the pancreas in rats with experimental diabetes mellitus. Bull Exp Biol Med. 2007;143(3):368–371.
- Khavinson VKh, et al. Advances in gerontology. 2012;25(4):680–684.
- Khavinson VKh, et al. Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide. Bull Exp Biol Med. 2010;149(3):351–353.
- Ashapkin VV, et al. Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Biochemistry. 2015;80(3):310–322.
Disclaimer: The information provided is intended solely for educational and scientific discussion. The compounds described are strictly intended for laboratory research and in-vitro studies only. They are not approved for human or animal consumption, medical use, or diagnostic purposes. Handling is prohibited unless performed by licensed researchers and qualified professionals in controlled laboratory environments.
